Atorvastatin Versus Simvastatin In The Prevention Of Coronary Heart Disease (CHD) In Patients With Known CHD

Pfizer8,600 enrolled

Overview

To investigate whether a long-term strategy to lower LDL cholesterol with atorvastatin as much as possible will improve prognosis in CHD patients compared with a strategy reflecting current best clinical practice with simvastatin.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

8,600

Conditions

Cardiovascular Diseases

Interventions

atorvastatinDRUG

simvastatinDRUG

Eligibility

Sex: ALLMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Previous myocardial infarction Exclusion Criteria: * Women who are breast feeding or are pregnant

Locations (194)

Outcomes

Primary Outcomes

Time to of a major coronary event: 1) non-fatal acute myocardial infarction 2) coronary death 3) resuscitated cardiac arrest

Secondary Outcomes

1) Time to any CHD event, 2) Time to Hospitalization with primary diagnosis of CHF, 3) Time to Cerbrovascular Event, 4) Time to PAD, 5) Time to any CV event and 6) All Cause Mortality

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Pfizer Investigational Site

Arhus C, Denmark

Pfizer Investigational Site

Copenhagen, Denmark

Pfizer Investigational Site

Elsinore, Denmark

Pfizer Investigational Site

Esbjerg, Denmark

Pfizer Investigational Site

Fredericia, Denmark

Pfizer Investigational Site

Frederiksberg, Denmark

Pfizer Investigational Site

Frederikssund, Denmark

Pfizer Investigational Site

Grenå, Denmark

Pfizer Investigational Site

Hjørring, Denmark

Pfizer Investigational Site

Holbak, Denmark

...and 184 more locations